BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zegfrovy (Sunvozertinib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Zegfrovy (Sunvozertinib)\, from ClinicalT
 rials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06864624-2163@assetmemo.bio
DTSTAMP:20261121T005912Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Zegfrovy (Sunvozertinib): Phase 2 readout est. (NCT06864624)
DESCRIPTION:Zegfrovy (Sunvozertinib)\, phase 2\, Non-Small Cell Lung Cancer
 .\nStudy: Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLC\
 nEstimated primary completion: December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/sunvozertinib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06864624
URL:https://assetmemo.bio/drug/sunvozertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05559645-2163@assetmemo.bio
DTSTAMP:20261121T005912Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Zegfrovy (Sunvozertinib): Phase na readout est. (NCT05559645)
DESCRIPTION:Zegfrovy (Sunvozertinib)\, phase na\, Non-Small Cell Lung Cance
 r.\nStudy: Assessing an Oral EGFR Inhibitor\, DZD9008 in Patients With Adv
 anced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)\nE
 stimated primary completion: 31 December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/sunvozertinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05559645
URL:https://assetmemo.bio/drug/sunvozertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07117890-2163@assetmemo.bio
DTSTAMP:20261121T005912Z
DTSTART;VALUE=DATE:20270220
DTEND;VALUE=DATE:20270221
SUMMARY:Zegfrovy (Sunvozertinib): Phase 2 readout est. (NCT07117890)
DESCRIPTION:Zegfrovy (Sunvozertinib)\, phase 2\, Non-Small Cell Lung Cancer
 .\nStudy: Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Un
 common Mutations\nEstimated primary completion: 20 February 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/sunvozertinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07117890
URL:https://assetmemo.bio/drug/sunvozertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06905197-2163@assetmemo.bio
DTSTAMP:20261121T005912Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Zegfrovy (Sunvozertinib): Phase 1 readout est. (NCT06905197)
DESCRIPTION:Zegfrovy (Sunvozertinib)\, phase 1\, Non-Small Cell Lung Cancer
 .\nStudy: A Multinational Study Assessing an Oral EGFR Inhibitor\, DZD6008
  in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)\nEst
 imated primary completion: September 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/sunvozertinib#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06905197
URL:https://assetmemo.bio/drug/sunvozertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563999-2163@assetmemo.bio
DTSTAMP:20261121T005912Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Zegfrovy (Sunvozertinib): Phase 2 readout est. (NCT06563999)
DESCRIPTION:Zegfrovy (Sunvozertinib)\, phase 2\, Non-Small Cell Lung Cancer
 .\nStudy: Neoadjuvant Umbrella Trial for Patients With Unresectable Stage 
 III NSCLC Harboring Rare Mutations.\nEstimated primary completion: 1 Novem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sunvozertin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6563999
URL:https://assetmemo.bio/drug/sunvozertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06195189-2163@assetmemo.bio
DTSTAMP:20261121T005912Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Zegfrovy (Sunvozertinib): Phase 1/2 readout est. (NCT06195189)
DESCRIPTION:Zegfrovy (Sunvozertinib)\, phase 1/2\, Non-Small Cell Lung Canc
 er.\nStudy: Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-
 TKI Treatment Failure：Phase I/II\nEstimated primary completion: 30 Decem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sunvozertin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6195189
URL:https://assetmemo.bio/drug/sunvozertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07079475-2163@assetmemo.bio
DTSTAMP:20261121T005912Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Zegfrovy (Sunvozertinib): Phase 1/2 readout est. (NCT07079475)
DESCRIPTION:Zegfrovy (Sunvozertinib)\, phase 1/2\, Non-Small Cell Lung Canc
 er.\nStudy: Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertin
 ib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)\nE
 stimated primary completion: June 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/sunvozertinib#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07079475
URL:https://assetmemo.bio/drug/sunvozertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07182682-2163@assetmemo.bio
DTSTAMP:20261121T005912Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Zegfrovy (Sunvozertinib): Phase 3 readout est. (NCT07182682)
DESCRIPTION:Zegfrovy (Sunvozertinib)\, phase 3\, Non-Small Cell Lung Cancer
 .\nStudy: A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Ther
 apy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR
  Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery\nEsti
 mated primary completion: September 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/sunvozertinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07182682
URL:https://assetmemo.bio/drug/sunvozertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07274761-2163@assetmemo.bio
DTSTAMP:20261121T005912Z
DTSTART;VALUE=DATE:20300501
DTEND;VALUE=DATE:20300502
SUMMARY:Zegfrovy (Sunvozertinib): Phase 2 readout est. (NCT07274761)
DESCRIPTION:Zegfrovy (Sunvozertinib)\, phase 2\, Non-Small Cell Lung Cancer
 .\nStudy: Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung C
 ancer Harboring EGFR Exon 20 Insertion Mutation.\nEstimated primary comple
 tion: 1 May 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sun
 vozertinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07274761
URL:https://assetmemo.bio/drug/sunvozertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
